These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8519672)

  • 21. A phase II study of interferon alpha and low-dose subcutaneous interleukin-2 in advanced renal cell carcinoma.
    Piga A; Giordani P; Quattrone A; Giulioni M; De Signoribus G; Antognoli S; Cellerino R
    Cancer Immunol Immunother; 1997 Aug; 44(6):348-51. PubMed ID: 9298938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
    Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
    Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
    Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
    Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential subcutaneous thymopentin, interferon alpha-2a and interleukin-2 in metastatic renal cell cancer.
    Di Lauro L; Del Medico P; Carpano S; Cancrini A; Gionfra T; Vici P; Rosselli M; Lopez M
    Tumori; 1995; 81(1):42-4. PubMed ID: 7754540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematotoxicity of interleukin-2 in man: clinical effects and comparison of various treatment regimens.
    Schomburg A; Kirchner H; Atzpodien J
    Acta Haematol; 1993; 89(3):119-31. PubMed ID: 8362600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
    Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
    J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM; Pfister C; Berdah JF; Benhammouda A; Salze P; Monnier A; Paule B; Guillet P; Chretien Y; Brewer Y; Di Palma M; Untereiner M; Malaurie E; Tadrist Z; Pavlovitch JM; Hauteville D; Mejean A; Azagury M; Mayeur D; Lucas V; Krakowski I; Larregain-Fournier D; Abourachid H; Andrieu JM; Chastang C
    J Clin Oncol; 1998 Jul; 16(7):2505-13. PubMed ID: 9667271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma.
    Buzio C; Andrulli S; Santi R; Pavone L; Passalacqua R; Potenzoni D; Ferrozzi F; Giacosa R; Vaglio A
    Cancer; 2001 Nov; 92(9):2286-96. PubMed ID: 11745283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.
    Clark JI; Mehrabi J; Sosman JA; Logan TF; Margolin KA; Dutcher JP; Urba WJ; Ernstoff MS; McDermott DF; Lau AM; Atkins MB
    J Immunother; 2007; 30(8):839-46. PubMed ID: 18049336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial.
    Ravaud A; Trufflandier N; Ferrière JM; Debled M; Palussière J; Cany L; Gaston R; Mathoulin-Pélissier S; Bui BN
    Br J Cancer; 2003 Dec; 89(12):2213-8. PubMed ID: 14676797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma.
    Clark JI; Gaynor ER; Martone B; Budds SC; Manjunath R; Flanigan RC; Waters WB; Sosman JA
    Clin Cancer Res; 1999 Sep; 5(9):2374-80. PubMed ID: 10499607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.
    De Mulder PH; Oosterhof G; Bouffioux C; van Oosterom AT; Vermeylen K; Sylvester R
    Br J Cancer; 1995 Feb; 71(2):371-5. PubMed ID: 7841054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of advanced renal cell carcinoma with subcutaneous administration of interleukin 2 and interferon-alpha].
    Hofmockel G; Theiss M; Bussen D; Wirth MP; Frohmüller HG
    Urologe A; 1994 Sep; 33(5):434-9. PubMed ID: 7974933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
    Lopez Hänninen E; Kirchner H; Atzpodien J
    J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical experience with the treatment of metastatic renal cell carcinoma with subcutaneous interleukin-2r (IL-2r) and interferon Alpha-2b (IFN Alfa-2b)].
    Olivier C; Carballido J; Lao AH; Gimeno A; Martín C; Renjifo D; Ondina LM; Manzano L; Alvarez-Mon M
    Actas Urol Esp; 1995 Jan; 19(1):16-26. PubMed ID: 7717154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
    Marincola FM; White DE; Wise AP; Rosenberg SA
    J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of very low doses of immunotherapy in advanced renal cell cancer.
    Buzio C; De Palma G; Passalacqua R; Potenzoni D; Ferrozzi F; Cattabiani MA; Manenti L; Borghetti A
    Br J Cancer; 1997; 76(4):541-4. PubMed ID: 9275034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.
    Ilson DH; Motzer RJ; Kradin RL; Vogelzang NJ; Bajorin DF; Scher HI; Nanus D; O'Moore P; Marathias K; Bosl GJ
    J Clin Oncol; 1992 Jul; 10(7):1124-30. PubMed ID: 1607918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.